Can Mabwell’s ADC 7MW4911 overcome drug resistance in late-stage GI cancers?
Mabwell begins U.S. trial of novel CDH17-targeting ADC 7MW4911 for resistant GI cancers. Learn what makes this payload and target combination clinically unique.
AI in clinical operations: Can PhaseV’s real-time site optimization reshape IBD trial efficiency?
Find out how PhaseV’s AI-powered ClinOps Optimizer is changing IBD trial site selection with causal ML and real-time analytics. Read the full analysis.
Replacing microbiota rejuvenates aging gut tissue: What new mouse data means for regenerative GI therapies
A mouse study suggests young microbiota can rejuvenate aging gut tissue. Find out what this could mean for regenerative GI therapies and IBD care.
What MDLifespan’s plasma exchange expansion reveals about toxin burden and aging medicine
Find out how MDLifespan and Cenegenics are redefining plasma exchange for inflammation and toxin removal. Could this reshape preventive health care?
FAR Biotech expands to Madison: What this means for AI-based drug development
FAR Biotech brings its QuantumAI platform to Madison. Find out what this move means for drug discovery, platform scalability, and Wisconsin’s biohealth future.
Veloxis Pharmaceuticals’ pegrizeprument gets orphan status—will FDA incentives accelerate clinical momentum?
Veloxis earns FDA orphan status for pegrizeprument in liver transplant rejection. Find out what this means for the future of immunosuppressive therapy.
Resolve M Therapeutics exits stealth with Johnson & Johnson Innovation support to pursue MS1-driven immune resolution
Resolve M exits stealth with a bold MS1-based approach to inflammation. Learn how its pro-resolution platform could reshape autoimmune drug development.
Can philanthropic capital succeed where pharma failed in Gram-negative antibiotic discovery?
Will Gr-ADI fix the broken antibiotic pipeline? Explore how Gates, Novo, and Wellcome aim to reboot AMR innovation with $60M in global grants.
Avacta Therapeutics (LSE: AVCT) advances FAP-targeting drug conjugate AVA6103 into Phase 1: What’s at stake?
Avacta Therapeutics (LSE: AVCT) has received Investigational New Drug (IND) clearance from the United States Food and Drug Administration for AVA6103 (also known as FAP-Exd), its second clinical-stage asset developed using the company’s proprietary pre|CISION platform. The IND clearance enables the start of a Phase 1 trial evaluating the safety, tolerability, and dose parameters of […]
How Insilico Medicine’s ISM8969 could unlock a new class of neuroinflammatory drugs
Insilico’s AI-designed drug ISM8969 enters Phase 1 for Parkinson’s disease. Find out what this NLRP3 candidate could mean for CNS drug development.